News
Public · Published
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
AN2 Therapeutics said the U.S. FDA cleared its Investigational New Drug application for oral epetraborole in polycythemia vera, a blood disorder. The company also said it has authorizations in Australia, India, and the U.S. for its planned global Phase 2 study, which it expects to start in the fourth quarter of 2026.
Published:
Updated:
What happened
AN2 Therapeutics said the U.S. FDA cleared its Investigational New Drug application for oral epetraborole in polycythemia vera, a blood disorder. The company also said it has authorizations in Australia, India, and the U.S. for its planned global Phase 2 study, which it expects to start in the fourth quarter of 2026.
Confirmed
Global impact / market context
The clearance removes a regulatory step needed before the planned U.S. portion of the study can proceed, while authorizations across three countries support the intended global trial. If the study produces useful results, it could inform whether epetraborole advances further, but efficacy and commercial value remain unproven.
Analyst inference
The announcement concerns clinical development, not an approved treatment or reported trial results. The planned study includes an initial open-label group, where treatment is not masked, followed by a randomized, placebo-controlled group, which compares treatment with an inactive substitute; the company has not reported outcomes.
Confirmed
What to watch
- Watch for the company to begin the Phase 2 study in the fourth quarter of 2026 as expected; a delay would push back when trial evidence may emerge. Analyst inference
- Look for enrollment and dose-selection details from Part 1, which is an open-label cohort intended to help choose the dose for the later study group. Analyst inference
- Future results should show whether epetraborole controls hematocrit, the proportion of blood made up of red cells; the company says this is a development rationale, not proven benefit. Analyst inference
Evidence
- Original source link unavailable